Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
BRISBANE, Calif., Nov. 08, 2016 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Dr. Peter Maag, Chief Executive Officer, and Charles Constanti, Chief Financial Officer, will be participating in four upcoming investor conferences:
Mizuho Global Investor Conference in New York City
- Dr. Peter Maag and Charles Constanti will participate in one-on-one meetings on Monday, November 14, 2016
7th Annual Craig-Hallum Alpha Select Conference in New York City
- Dr. Peter Maag and Charles Constanti will present on Wednesday, November 16, 2016 at 11:50am PT/2:50pm ET.
28th Annual Piper Jaffray Healthcare Conference in New York City
- Dr. Peter Maag and Charles Constanti will present on Tuesday, November 29, 2016 at 11:00am PT/1:00pm ET.
Evercore ISI MedTools Investor Conference in Boston, MA
- Dr. Peter Maag and Charles Constanti will participate in one-on-one meetings on December 1, 2016.
A live audio webcast of the Craig-Hallum Alpha Select and Piper Jaffray Healthcare conferences presentations will be available online from the Investor Relations page of the Company's website at http://investors.caredxinc.com. The webcast replay of each presentation will be available on the Company's website for 90 days. Due to the one-on-one only format of the Mizuho and Evercore ISI MedTools conferences, no webcasts will be available.
About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, diagnostic solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying risk of rejection in heart transplant recipients.
CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. For more information, please visit: www.CareDx.com.
CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. For more information, please visit: www.CareDx.com.
Investor Relations Contact Jamar Ismail, Vice President Westwicke Partners, LLC T: +1 415-513-1282 E: [email protected]
